GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (STU:0C8) » Definitions » Net Income (Continuing Operations)

Catalent (STU:0C8) Net Income (Continuing Operations) : €-1,095 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Catalent Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Catalent's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was €-93 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1,095 Mil.


Catalent Net Income (Continuing Operations) Historical Data

The historical data trend for Catalent's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Net Income (Continuing Operations) Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.25 196.25 485.55 472.05 -236.29

Catalent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -212.02 -101.53 -711.18 -188.90 -92.92

Catalent Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,095 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalent  (STU:0C8) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Catalent Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Catalent's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (STU:0C8) Business Description

Industry
Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Catalent (STU:0C8) Headlines

No Headlines